June 28, 2025 06:00 AM EDT

Sources say FDA commissioner sought rejection of KalVista’s rare disease drug; FDA looks into Sarepta’s Duchenne therapy after deaths; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Welcome back to Endpoints Weekly! Thanks for spending your Saturday with us. We start this week’s recap with reporting from Endpoints News’ senior biopharma correspondent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sources say FDA commissioner sought rejection of KalVista’s rare disease drug; FDA looks into Sarepta’s Duchenne therapy after deaths; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Sign up to read this article for free.

J&J dealt blow in fight over its 340B rebate model

Updated: Amgen plans lower, slower MariTide doses for obesity drug’s Phase 3

Acting CDER chief is leaving after almost nine years at FDA

A dinner in Paris revived talks for Sanofi's $9.5B deal for Blueprint

FDA loosens safety requirements for CAR-Ts in move to boost access

Digital Twins in GMP Manufacturing: Shaping the Future of CPV with Aizon

Sources say FDA com­mis­sion­er sought re­jec­tion of KalVista’s rare dis­ease drug; FDA looks in­to Sarep­ta’s Duchenne ther­a­py af­ter deaths; and more

Editor

Senior Editor

Sign up to read this article for free.

Sources say FDA commissioner sought rejection of KalVista’s rare disease drug; FDA looks into Sarepta’s Duchenne therapy after deaths; and more